Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma

Demirci, Hakan; Kauh, Courtney Y.; Rajaii, Fatemeh; Elner, Victor M.

doi:10.1097/iop.0000000000000666

Cited by 12 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Demirci et al describes a patient with a history of Sjögren syndrome with recurrence of bilateral lacrimal gland EMZL after completion of systemic rituximab therapy. The patient was then treated with intralesional rituximab and remained free from recurrence at 23 and 30 months of follow-up [110]. Rodríguez Villa et al documented a case of previously untreated unilateral FL of the conjunctiva that resolved with intralesional rituximab [111].…”

Section: Reviewmentioning

confidence: 99%

Classification, diagnosis, and management of conjunctival lymphoma

2019

View full text Add to dashboard Cite

Lymphoma is a malignant lymphoproliferative tumor that can involve the conjunctiva. Approximately 5–15% of all extranodal lymphomas are found in the ocular adnexal region, with approximately 25% of those involving the conjunctiva. Ninety-eight percent of conjunctival lymphomas arise from B-lymphocytes. The most common subtype of conjunctival lymphoma is extranodal marginal zone lymphoma (80%), followed by follicular lymphoma (8%), diffuse large B-cell lymphoma (3%) and mantle cell lymphoma (3%). Natural killer and T cells (NK/T) are rare causes of lymphoma. While most conjunctival lymphomas are localized to the ocular adnexa at the time of presentation, systemic examination and management are of key importance in the long-term care of the patient. This review outlines the classification, etiology, presentation, diagnosis, and management of conjunctival lymphoma. The novel use of high resolution optical coherence tomography, both as a diagnostic tool and as a means for ongoing evaluation during treatment, is illustrated. Treatment options discussed include external beam radiation, chemotherapy, immunotherapy, antibiotic therapy, and combination regimens. Future investigation of the etiology and pathogenesis of conjunctival lymphoma is expected to reveal opportunities for innovative and individualized therapeutic agents. Collaboration between multiple disciplines is key in the advancement of the field.

show abstract

Section: Reviewmentioning

confidence: 99%

Classification, diagnosis, and management of conjunctival lymphoma

2019

View full text Add to dashboard Cite

show abstract

“…Während das diffus großzellige B-Zell-Lymphom meist unilateral auftritt, überwiegt beim MALT-Lymphom eine diffuse Ausbreitung [357]. Die Therapie besteht bei lokaler Manifestation in einer Strahlentherapie, bei systemischer Manifestation in einer Chemotherapie, beim MALT-Lymphom in Kombination mit Rituximab [333,357,360].…”

Section: Maligne Lymphomeunclassified

Interdisziplinäre Therapie der Erkrankungen der Orbita

Eckstein,

Welkoborsky

2024

Laryngorhinootologie

View full text Add to dashboard Cite

ZusammenfassungDie Diagnostik und Therapie von Erkrankungen der Orbita ist eine interdisziplinäre Aufgabe, an der u.a. die Fachdisziplinen HNO-Heilkunde, Augenheilkunde, Radiologie, Strahlentherapie, MKG-Chirurgie, Endokrinologie und Pädiatrie beteiligt sind. Der vorliegende Übersichtsartikel stellt eine Zusammenstellung der häufigsten Erkrankungen dar, mit denen die Fachdisziplinen HNO-Heilkunde und Augenheilkunde interdisziplinär befasst sind. Es werden die akuten entzündlichen Erkrankungen incl. orbitaler Komplikationen, die autoimmunologischen Erkrankungen der Orbita incl. der endokrinen Orbitopathie, und die tumorösen Erkrankungen besprochen. Neben der Diagnostik und der Beschreibung der Klinik wird besonderes Augenmerk auf die interdisziplinäre Therapie gelegt. Abgerundet wird der Übersichtsartikel mit der Beschreibung der wichtigsten chirurgischen Zugangswege zur Orbita, ihre Indikationen und mögliche Komplikationen. Die Autoren haben versucht, trotz der knappen Darstellung die relevanten Fakten zu beschreiben.

show abstract

“…The most commonly affected sites are the orbit (40%), followed by the conjunctiva (35%–40%), lacrimal gland (10%–15%), and eyelid (10%) 14,15 . A review conducted by Demirci et al of 160 orbital lymphomas found that the upper orbit was affected in 64%, the lower orbit in 9%, the temporal lobe in 8%, the nasal area in 8%, and the central region in 11% 16 …”

Section: Introductionmentioning

confidence: 99%

“…14,15 A review conducted by Demirci et al of 160 orbital lymphomas found that the upper orbit was affected in 64%, the lower orbit in 9%, the temporal lobe in 8%, the nasal area in 8%, and the central region in 11%. 16 Of all OALs, 98% are B-cell lymphomas, with the most common subtype being mucosa-associated lymphoid tissue marginal zone B-cell lymphoma (MALT) (49%-64%), followed by follicular lymphoma (FL) (10%-23%) and diffuse large B-cell lymphoma (DLBCL) (8%-10%), less common subtypes include mantle cell lymphoma (MCL) (5%-9%) and chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) (4%-7%). T cell lymphoma (TCL), on the other hand, is extremely rare and represents only 2% of all OALs.…”

mentioning

confidence: 99%

Clinical analysis of 94 cases of ocular adnexal lymphomas

Sun,

Luo,

Huang

2024

Precision Medical Sciences

View full text Add to dashboard Cite

To investigate the imaging manifestations and pathological features of ocular adnexal lymphoma (OALs) in order to provide relevant information for ophthalmologists. A total of 94 patients with OALs were pathologically confirmed between August 2018 and July 2023, and their demographics, location, subtype, treatment, and prognosis were retrospectively studied. 94 patients with OALs were included in this study, of whom 28 were female (29.79%) and 66 were male (70.21%). The age of the patients ranged from 21 to 80 years, with a predominance of 50–60 years (60/94); monocular onset was common (90/94), and the most site of onset was orbital (74/94), followed by conjunctiva (12/94), eyelids (4/94), vitreous (3/94), and lacrimal gland (1/94). CT and MRI can show the involvement and extent of the lesions, and the pathology of the disease is characterized by mucosa‐associated lymphoid tissue marginal zone B‐cell lymphoma (72/94), diffuse large B‐cell lymphoma (10/94), T‐cell lymphoma (4/94), mantle cell lymphoma (2/94), Burkitt's lymphoma (2/94), small lymphocytic lymphoma (2/94), and follicular lymphoma (1/94). All patients received surgical treatment, 42 patients received local radiation therapy, 35 patients received chemotherapy, 13 patients received radiation therapy and chemotherapy successively, and 3 patients received comprehensive treatment. During the follow‐up, three patients relapsed, four died, one was lost to follow‐up, and the remaining patients had stable conditions. The majority of OALs are mucosa‐associated lymphoid tissue marginal zone B‐cell lymphomas (MALT) with an excellent prognosis. It mostly occurs in people over 50 years of age and most site of the onset is orbital.

show abstract

Intralesional Rituximab for the Treatment of Recurrent Ocular Adnexal Lymphoma

Cited by 12 publications

References 4 publications

Classification, diagnosis, and management of conjunctival lymphoma

Classification, diagnosis, and management of conjunctival lymphoma

Interdisziplinäre Therapie der Erkrankungen der Orbita

Clinical analysis of 94 cases of ocular adnexal lymphomas

Contact Info

Product

Resources

About